<SEC-DOCUMENT>0001193125-21-324503.txt : 20211109
<SEC-HEADER>0001193125-21-324503.hdr.sgml : 20211109
<ACCEPTANCE-DATETIME>20211109162112
ACCESSION NUMBER:		0001193125-21-324503
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20211109
DATE AS OF CHANGE:		20211109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DELCATH SYSTEMS, INC.
		CENTRAL INDEX KEY:			0000872912
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				061245881
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-257428
		FILM NUMBER:		211392518

	BUSINESS ADDRESS:	
		STREET 1:		1633 BROADWAY
		STREET 2:		SUITE 22C
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		(212) 489-2100

	MAIL ADDRESS:	
		STREET 1:		1633 BROADWAY
		STREET 2:		SUITE 22C
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DELCATH SYSTEMS INC
		DATE OF NAME CHANGE:	19990607
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d236723d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5)<BR>Registration No. 333-257428 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(To Prospectus dated
July&nbsp;2, 2021) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g236723g70x52.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Up to $25,000,000 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We previously entered into
a Controlled Equity Offering<SUP STYLE="font-size:85%; vertical-align:top">SM</SUP> Sales Agreement, or sales agreement, with Cantor Fitzgerald&nbsp;&amp; Co., or Cantor Fitzgerald, relating to shares of our common stock, $0.01 par value per share,
offered by this prospectus supplement and the accompanying prospectus. Pursuant to this prospectus supplement and the accompanying prospectus, we may from time to time offer and sell shares of our common stock having aggregate gross proceeds of up
to $25.0&nbsp;million through Cantor Fitzgerald, acting as sales agent. In our fiscal year ended December&nbsp;31, 2020, we sold a total of 77,644 shares of our common stock through Cantor Fitzgerald, our sales agent under the sales agreement, for
total gross proceeds of approximately $910,000, pursuant to a prospectus supplement dated August&nbsp;18, 2020 and an accompanying prospectus dated December&nbsp;21, 2018 included in a shelf registration statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> filed with the Securities and Exchange Commission and declared effective on December&nbsp;21, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common
stock is listed on The Nasdaq Capital Market under the symbol &#147;DCTH.&#148; On November&nbsp;5, 2021, the last reported sale price of our common stock on The Nasdaq Capital Market was $11.72 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of our common stock, if any, under this prospectus supplement may be made in sales deemed to be an &#147;at the market offering&#148; as defined in Rule
415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. Subject to the terms of the sales agreement, Cantor Fitzgerald is not required to sell any specific number or dollar amounts of securities but will act as our
sales agent using commercially reasonable best efforts consistent with its normal trading and sales practices, on mutually agreed terms between Cantor Fitzgerald and us. There is no arrangement for funds to be received in any escrow, trust or
similar arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald will be entitled to compensation under the terms of the sales agreement at a fixed commission rate of 3.0% of the
gross sales price per share sold. In connection with the sale of our common stock on our behalf, Cantor Fitzgerald will be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act and the compensation of Cantor Fitzgerald
will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contributions to Cantor Fitzgerald against certain civil liabilities, including liabilities under the Securities Act. See &#147;Plan of
Distribution&#148; beginning on page S-15 of this prospectus supplement for more information regarding our arrangements with the sales agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investing in our common stock involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#147;<A HREF="#supprom236723_4">Risk
 Factors</A>&#148; on page S-6 of this prospectus supplement, and under similar headings in the documents that are incorporated by reference into this prospectus supplement and the accompanying prospectus. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this
prospectus supplement and the accompanying prospectus are truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g236723g97w67.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is November&nbsp;9, 2021. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center"><B>Prospectus Supplement</B></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom236723_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom236723_2">PROSPECTUS SUPPLEMENT SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom236723_3">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom236723_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom236723_5">CAUTIONARY NOTE CONCERNING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom236723_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom236723_7">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom236723_8">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom236723_9">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom236723_10">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom236723_11">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom236723_12">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom236723_13">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx236723_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx236723_2">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx236723_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx236723_4">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx236723_5">DESCRIPTION OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx236723_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx236723_7">RATIO OF EARNINGS TO FIXED CHARGES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx236723_8">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx236723_9">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx236723_10">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx236723_11">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx236723_12">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom236723_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus form part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and the
amendments thereto that we filed with the Securities and Exchange Commission, or the &#147;SEC&#148;, using a &#147;shelf&#148; registration process relating to the Common Stock described in this prospectus supplement, which registration statement
was declared effective on July&nbsp;2, 2021. Before buying any of the common stock that we are offering, we urge you to carefully read this entire prospectus supplement and the accompanying prospectus, together with the documents incorporated by
reference that are described under the headings &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Documents by Reference&#148; on pages S-17 and <FONT STYLE="white-space:nowrap">S-18</FONT> of this prospectus
supplement. These documents contain important information that you should consider when making your investment decision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise specified or
required by context, references in this prospectus supplement to the &#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to Delcath Systems, Inc., a Delaware corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document is in two parts. The first part is this prospectus supplement, which describes the terms of this offering and also adds to, updates and changes
information contained in the accompanying prospectus and the documents incorporated by reference into the accompanying prospectus. The second part is the accompanying prospectus, which gives more general information about the Company and the
securities that we may offer from time to time under our shelf registration statement, some of which may not apply to the common stock offered by this prospectus supplement. Generally, when we refer to this prospectus, we are referring to both parts
of this document combined. To the extent the information contained in this prospectus supplement differs from or conflicts with the information contained in the accompanying prospectus or any document incorporated by reference into the accompanying
prospectus, the information in this prospectus supplement will control. If any statement in one of these documents is inconsistent with a statement in another document having a later date&#151;for example, a document incorporated by reference into
this prospectus supplement and the accompanying prospectus&#151;the statement in the document having the later date modifies or supersedes the earlier statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not, and the sales agent has not, authorized anyone to provide you with information different from that which is contained in or incorporated by
reference in this prospectus supplement, the accompanying prospectus and in any free writing prospectus that we may authorize for use in connection with this offering. No one is making offers to sell or seeking offers to buy our common stock in any
jurisdiction where the offer or sale is not permitted. You should assume that the information contained in this prospectus supplement is accurate as of the date on the front cover of this prospectus supplement only and that any information we have
incorporated by reference or included in the accompanying prospectus is accurate only as of the date given in the document incorporated by reference or as of the date of the prospectus, as applicable, regardless of the time of delivery of this
prospectus supplement, the accompanying prospectus, any related free writing prospectus, or any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since those dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is
incorporated by reference into this prospectus supplement or the accompanying prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such
agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and
covenants should not be relied on as accurately representing the current state of our affairs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement, the accompanying prospectus
and the information incorporated herein and therein by reference may include trademarks, service marks and trade names owned or licensed by us, including CHEMOFUSE, CHEMOSAT, CHEMOSATURATION, DELCATH, HEPZATO, PHP and THE DELCATH
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
PHP SYSTEM. Solely for convenience, trademarks and trade names, including logos, artwork and other visual displays, may appear without the &reg; or TM symbols, but such references are not
intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks, service marks and trade names. All trademarks, service marks and trade
names included or incorporated by reference into this prospectus supplement or the accompanying prospectus are the property of the Company or the Company&#146;s licensor, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information contained on, or that can be accessed through, our website does not constitute part of this prospectus supplement, the accompanying prospectus or
any related free writing prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom236723_2"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary highlights certain information about us and this offering and selected information contained elsewhere in or incorporated by reference into
this prospectus supplement and the accompanying prospectus. This summary is not complete and does not contain all of the information that you should consider before deciding whether to invest in our common stock. For a more complete understanding of
the Company and this offering, we encourage you to read and consider carefully the more detailed information in this prospectus supplement and the accompanying prospectus, including the information incorporated by reference into this prospectus
supplement and the accompanying prospectus, and the information included in any free writing prospectus that we authorize for use in connection with this offering, including the information contained in and incorporated by reference under the
heading &#147;Risk Factors&#148; beginning on page S-6 of this prospectus supplement, and under similar headings in the other documents that are filed after the date hereof and incorporated by reference into this prospectus supplement and the
accompanying prospectus. </I></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Our Business </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an interventional oncology company
focused on the treatment of primary and metastatic liver cancers. Our lead product candidate, the HEPZATO<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> KIT (melphalan hydrochloride for injection/hepatic delivery system), or HEPZATO<SUP
STYLE="font-size:85%; vertical-align:top">&#153;</SUP>, is a drug/device combination product. HEPZATO is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, our
commercial product is a stand-alone medical device having the same device components as the HEPZATO KIT but without the melphalan hydrochloride and is approved for sale under the trade name
CHEMOSAT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our clinical development program for HEPZATO is primarily comprised of the FOCUS Clinical Trial for Patients with Hepatic Dominant Ocular Melanoma (FOCUS
Trial), a global registration clinical trial that is investigating objective response rate in metastatic ocular melanoma, or mOM. We are currently reviewing the incidence, unmet need, available efficacy data and development requirements for a broad
set of liver cancers in order to select a portfolio of <FONT STYLE="white-space:nowrap">follow-on</FONT> indications which will maximize the value of the HEPZATO platform. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated in the State
of Delaware in August 1988. Our principal executive offices are located at 1633 Broadway, Suite 22C, New York, New York 10019. Our telephone number is (212) <FONT STYLE="white-space:nowrap">489-2100.</FONT> Our website address is
<U>www.delcath.com</U>. Information contained in our website does not constitute any part of, and is not incorporated into, this prospectus supplement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being a Smaller Reporting Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are
a &#147;smaller reporting company&#148; as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act, and have elected to take advantage of certain of the scaled disclosures available to smaller reporting companies. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom236723_3"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Common stock offered by us</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Shares of our common stock, par value $0.01 per share, with aggregate gross proceeds of up to $25.0&nbsp;million.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Common Stock outstanding immediately after this Offering</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to 9,489,394 shares of our common stock, assuming sales of 2,133,105 shares of our common stock in this offering at an assumed offering price of $11.72 per share, which was the last reported sale price of our common stock on The
Nasdaq Capital Market on November&nbsp;5, 2021. The actual number of shares issued will vary depending on the sales prices at which our common stock is sold under this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Plan of Distribution</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#147;At the market offering&#148; that may be made from time to time through our sales agent, Cantor Fitzgerald. See &#147;Plan of Distribution&#148; on page S-15 of this prospectus supplement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Use of Proceeds </B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">We intend to use the net proceeds from this offering for working capital and general corporate purposes, which may include capital expenditures, debt repayment, and research and development, sales and marketing and general and
administrative expenses. See &#147;Use of Proceeds&#148; on page <FONT STYLE="white-space:nowrap">S-11</FONT> of this prospectus supplement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Risk Factors </B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Investing in our common stock involves a high degree of risk. See the information contained in or incorporated by reference under the heading &#147;Risk Factors&#148; on page <FONT STYLE="white-space:nowrap">S-6</FONT> of this
prospectus supplement, in the accompanying prospectus and in the documents incorporated by reference into this prospectus supplement and any free writing prospectus that we authorize for use in connection with this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>The Nasdaq Capital Market symbol</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">DCTH</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Outstanding Shares</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on 7,356,289 shares of our common stock outstanding
as of September&nbsp;30, 2021, and excludes the following:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;1,170,721 shares of common stock reserved for issuance pursuant to the conversion of 11,707.21
shares of preferred stock, based on the $10.00 conversion price in effect as of September&nbsp;30, 2021;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;3,610,754 shares of our common stock reserved for issuance upon exercise
of</P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:0.00em; font-size:10pt; font-family:Times New Roman">outstanding warrants having a weighted average exercise price of $10.00 per share at September&nbsp;30, 2021;<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;283,755 shares of common stock reserved for issuance upon exercise of outstanding warrants having
an exercise price of $0.01 per share;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;1,698,249 shares of our common stock reserved for issuance upon exercise of outstanding options
having a weighted average exercise price of $11.71 per share; and</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;488,031 shares of our common stock underlying the assumed conversion of convertible notes based on
the conversion price in effect as of September&nbsp;30, 2021.</P></TD></TR>
</TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom236723_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. You should carefully review the risks and uncertainties described below and discussed under
the caption &#147;Risk Factors&#148; in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2020, as updated by our most recent quarterly reports on Form
<FONT STYLE="white-space:nowrap">10-Q,</FONT> which are filed with the SEC and incorporated by reference into this prospectus supplement, before deciding whether to purchase any common stock in this offering. Each of the risk factors could adversely
affect our business, operating results and financial condition, as well as adversely affect the value of an investment in our common stock, and the occurrence of any of these risks might cause you to lose all or part of your investment. Additional
risks not presently known to us or that we currently believe are immaterial may also significantly impair our business operations. Please also read carefully the section below entitled &#147;Cautionary Note Concerning Forward-Looking
Statements.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks related to this offering and our common stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion in how we use the net proceeds from this offering, and we may not use these proceeds effectively or in ways with which you
agree. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not designated any portion of the net proceeds from this offering to be used for any particular purpose. Our management will have
broad discretion as to the application of the net proceeds from this offering and could use them for purposes other than those contemplated at the time of this offering. Our stockholders may not agree with the manner in which our management chooses
to allocate and spend the net proceeds. Moreover, our management may use the net proceeds for corporate purposes that may not increase the market price of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may experience immediate and substantial dilution. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offering price per share of common stock in this offering may exceed the net tangible book value per share of our common stock outstanding prior to this
offering. Assuming that an aggregate of 2,133,105 shares of our common stock are sold at a price of $11.72 per share pursuant to this prospectus supplement, which was the last reported sale price of our common stock on The Nasdaq Capital Market on
November&nbsp;5, 2021, for aggregate gross proceeds of $25.0&nbsp;million, after deducting commissions and estimated aggregate offering expenses payable by us, you would experience immediate dilution of $7.94 per share, representing the difference
between our as adjusted net tangible book value per share as of September&nbsp;30, 2021 after giving effect to this offering and the assumed offering price. The conversion of preferred stock and the exercise of outstanding stock options and warrants
may result in further dilution of your investment. See &#147;Dilution&#148; in this prospectus supplement for a more detailed illustration of the dilution you would incur if you participate in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may experience future dilution as a result of future equity offerings. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable
for our common stock at prices that may not be the same as the price per share in this offering. We may sell shares or other securities in any other offering at a price per share that is less than the price per share paid by any investors in this
offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common stock, or securities convertible or exchangeable
into common stock, in future transactions may be higher or lower than the price per share paid by any investors in this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not intend
to pay dividends to the holders of our common stock in the foreseeable future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividend on our common
stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
declaring or paying any cash dividends for the foreseeable future. Our board of directors will have the sole discretion in determining whether to declare and pay dividends in the future. The
declaration of dividends will depend on profitability, financial condition, cash requirements, future prospects and other factors deemed relevant by our board of directors. In addition, our ability to pay cash dividends in the future could be
limited or prohibited by the terms of financing agreements that we may enter into or by the terms of any preferred stock that may be authorized and issued. We do not expect to pay dividends in the foreseeable future. As a result, holders of our
common stock must rely on stock appreciation for any return on their investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market price of our common stock has been, and may continue to
be volatile and fluctuate significantly, which could result in substantial losses for investors. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trading price of our common stock has been,
and we expect it to continue to be, volatile. The price at which our common stock trades depends upon a number of factors, including historical and anticipated operating results, our financial situation, announcements of technological innovations or
new products by us or our competitors, our ability or inability to raise the additional capital needed and the terms on which it may be raised, and general market and economic conditions. Some of these factors are beyond our control. Broad market
fluctuations may lower the market price of our common stock and affect the volume of trading, regardless of our financial condition, results of operations, business or prospects. Among the factors that may cause the market price of our common stock
to fluctuate are the risks described elsewhere in this &#147;Risk Factors&#148; section and other factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fluctuations in our quarterly operating results or the operating results of competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">variance in financial performance from the expectations of investors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the estimation of the future size and growth rate of our markets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in accounting principles or changes in interpretations of existing principles, which could affect
financial results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conditions and trends in the markets served; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in general economic, industry and market conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">success of competitive products and services; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in market valuations or earnings of competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in pricing policies or the pricing policies of competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements of significant new products, contracts, acquisitions or strategic alliances by us or our
competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potentially negative announcements, such as a review of any of our filings by the SEC, changes in accounting
treatment or restatements of previously reported financial results or delays in our filings with the SEC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in legislation or regulatory policies, practices or actions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commencement or outcome of litigation involving us, our general industry or both; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our filing for protection under federal bankruptcy laws; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in capital structure, such as future issuances of securities or the incurrence of additional debt;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or expected sales of common stock by stockholders; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the trading volume of our common stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the stock markets and the market for pharmaceutical companies in particular, may experience a loss of investor confidence. Such loss of investor
confidence may result in extreme price and volume fluctuations in our common stock that are unrelated or disproportionate to the operating performance of its business, financial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
condition or results of operations. These broad market and industry factors may materially harm the market price of our common stock and expose the Company to securities class action litigation.
Such litigation, even if unsuccessful, could be costly to defend and divert management&#146;s attention and resources, which could further materially harm our financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sales of a substantial number of shares of our&nbsp;common&nbsp;stock in the public market, or the perception that such sales may occur, could adversely
affect the market price of our&nbsp;common&nbsp;stock and could impair our ability to raise additional equity capital. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of a substantial
number of shares of our common stock&nbsp;in the public market, or the perception that such sales may occur, could cause the market price of our common stock to decline and could impair our ability to raise capital through the sale of additional
equity securities. We cannot predict the effect that future sales of shares of our&nbsp;common stock or other equity-related securities would have on the market price of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have a history of reverse splits, which have severely impacted our common stock price. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since our initial public offering in 2000, we have effected five reverse stock splits, for a cumulative ratio since our IPO of 1:31,360,000,000. Each such
reverse split has resulted in an effective decline in the price of our common stock. There can be no assurance that we will not be required to effect one or more additional reverse stock splits which could further impact the market price and
liquidity of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-takeover provisions in our Amended and Restated Certificate of Incorporation and
<FONT STYLE="white-space:nowrap">By-laws</FONT> may reduce the likelihood of a potential change of control or make it more difficult for our stockholders to replace management. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain provisions of our Amended and Restated Certificate of Incorporation and <FONT STYLE="white-space:nowrap">By-laws</FONT> could have the effect of
making it more difficult for our stockholders to replace management at a time when a substantial number of stockholders might favor a change in management. These provisions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">providing for a staggered board; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorizing the board of directors to fill vacant directorships or increase the size of the board of directors.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, our board of directors has the authority to issue up to 10,000,000 shares of preferred stock in one or more series and to
determine the rights and preferences of the shares of any such series without stockholder approval. Any series of preferred stock is likely to be senior to the common stock with respect to dividends, liquidation rights and, possibly, voting rights.
The board&#146;s ability to issue preferred stock may have the effect of discouraging unsolicited acquisition proposals, thus adversely affecting the market price of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we engage in acquisitions, reorganizations or business combinations, we will incur a variety of risks that could adversely affect our business
operations or our stockholders. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we may consider strategic alternatives, such as acquiring businesses, technologies or products
or entering into a business combination with another company. If we do pursue such a strategy, we could, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue equity securities that would dilute current stockholders&#146; percentage ownership; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur substantial debt that may place strains on our operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">spend substantial operational, financial and management resources in integrating new businesses, personnel,
intellectual property, technologies and products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assume substantial actual or contingent liabilities; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reprioritize our programs and even cease development and commercialization of CHEMOSAT and HEPZATO;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suffer the loss of key personnel, or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">merge with, or otherwise enter into a business combination with, another company in which our stockholders would
receive cash or shares of the other company or a combination of both on terms that certain of our stockholders may not deem desirable. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we intend to evaluate and consider different strategic alternatives, we have no agreements or understandings with respect to any acquisition,
reorganization, or business combination at this time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom236723_5"></A>CAUTIONARY NOTE CONCERNING FORWARD-LOOKING STATEMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement, the accompanying prospectus and the documents we have filed with the Securities and Exchange Commission, or SEC, that are
incorporated by reference herein contains certain &#147;forward-looking statements&#148; within the meaning of the &#147;safe harbor&#148; provisions of the Private Securities Litigation Reform Act of 1995 with respect to our business, financial
condition, liquidity and results of operations. Words such as &#147;anticipates,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;plans,&#148; &#147;predicts,&#148; &#147;believes,&#148; &#147;seeks,&#148; &#147;estimates,&#148;
&#147;could,&#148; &#147;would,&#148; &#147;will,&#148; &#147;may,&#148; &#147;can,&#148; &#147;continue,&#148; &#147;potential,&#148; &#147;should,&#148; and the negative of these terms or other comparable terminology often identify forward-looking
statements. Statements in this prospectus that are not historical facts are hereby identified as &#147;forward-looking statements&#148; for the purpose of the safe harbor provided by Section&nbsp;21E of the Securities Exchange Act of 1934, as
amended, or the Exchange Act, and Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could
cause actual results to differ materially from the results contemplated by the forward-looking statements. See &#147;Risk Factors&#148; beginning on page S-6. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding sufficiency of our cash resources, anticipated capital requirements and our need for
additional financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commencement of future clinical trials and the results and timing of those clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully commercialize CHEMOSAT and HEPZATO, generate revenue and successfully obtain
reimbursement for the procedure and system; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress and results of our research and development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission and timing of applications for regulatory approval and approval thereof; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully source certain components of CHEMOSTAT and HEPZATO and enter into supplier contracts;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully manufacture CHEMOSAT and HEPZATO; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully negotiate and enter into agreements with distribution, strategic and corporate
partners; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates of potential market opportunities and our ability to successfully realize these opportunities.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of the important factors that will determine these results are beyond our ability to control or predict. You are cautioned not to
put undue reliance on any forward-looking statements, which speak only as of the date of this prospectus. Except as otherwise required by law, we do not assume any obligation to publicly update or release any revisions to these forward-looking
statements to reflect events or circumstances after such applicable date or to reflect the occurrence of unanticipated events. You should, however, review the factors and risks we describe in the &#147;Risk Factors&#148; section hereof beginning on
page S-6 and in reports we will file from time to time with the SEC after the date of this prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom236723_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue and sell shares of our common stock in this offering for aggregate sales proceeds of up to $25.0&nbsp;million. Because there is no minimum
offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. There can be no assurance that we will sell any shares of our common
stock under or fully utilize the sales agreement with Cantor Fitzgerald as a source of financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from this offering
will be approximately $24.1 million, after deducting the sales agent&#146;s fees and the estimated expenses payable by us in connection with this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from this offering for working capital and general corporate purposes, which may include capital expenditures, debt
repayment, and research and development, sales and marketing and general and administrative expenses. We may also use a portion of the net proceeds from this offering to acquire or invest in businesses, products and technologies that are
complementary to our own, although we have no current plans, commitments or agreements with respect to any such acquisitions or investments as of the date of this prospectus supplement. We will retain broad discretion over the use of the net
proceeds from this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom236723_7"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between the price per
share you pay in this offering and the net tangible book value per share of our common stock immediately after this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our net tangible book value
as of September&nbsp;30, 2021 was approximately $11.7 million, or $1.59 per share. We calculate net tangible book value per share by dividing the net tangible book value, which is tangible assets less total liabilities, by the number of outstanding
shares of our common stock. Dilution represents the difference between the portion of the amount per share paid by purchasers of shares in this offering and the as adjusted net tangible book value per share of our common stock immediately after
giving effect to this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After giving effect to the assumed sale by us of 2,133,105 shares of our common stock in the aggregate amount of
$25.0&nbsp;million in this offering at an assumed offering price of $11.72 per share, which was the last reported sale price of our common stock on The Nasdaq Capital Market on November&nbsp;5, 2021 and after deducting commissions and estimated
aggregate offering expenses payable by us, our as adjusted net tangible book value as of September&nbsp;30, 2021 would have been approximately $35.9 million, or $3.78 per share of common stock. This represents an immediate increase in net tangible
book value per share of $2.19 to our existing stockholders and an immediate dilution in net tangible book value per share of $7.94 to new investors purchasing our common stock in this offering. The following table illustrates this dilution on a per
share basis to new investors participating in this offering. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-size:10pt">Assumed offering price per share</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><FONT STYLE="font-size:10pt">$11.72</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value/deficit per share as of September&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share of common stock attributable to investors purchasing
our common stock in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted net tangible book value per share of common stock immediately after this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table above assumes, for illustrative purposes, that an aggregate of 2,133,105 shares of our common stock are sold at a
price of $11.72 per share, the last reported sale price of our common stock on The Nasdaq Capital Market on November&nbsp;5, 2021, for aggregate gross proceeds of $25.0&nbsp;million. The shares sold in this offering, if any, will be sold from time
to time at various prices. An increase of $1.00 per share in the price at which the shares are sold from the assumed offering price of $11.72 per share shown in the table above, assuming the sale of $25.0&nbsp;million in shares at that price during
the term of the sales agreement with Cantor Fitzgerald, would increase our as adjusted net tangible book value per share after the offering to $3.85 per share and would increase the dilution in net tangible book value per share to new investors to
$8.87 per share, after deducting commissions and estimated aggregate offering expenses payable by us. A decrease of $1.00 per share in the price at which the shares are sold from the assumed offering price of $11.72 per share shown in the table
above, assuming the sale of $25.0&nbsp;million in shares at that price during the term of the sales agreement with Cantor Fitzgerald, would decrease our as adjusted net tangible book value per share after the offering to $3.70 per share and would
decrease the dilution in net tangible book value per share to new investors to $7.02 per share, after deducting commissions and estimated aggregate offering expenses payable by us. This information is supplied for illustrative purposes only and may
differ based on the actual offering price and the actual number of shares offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The above discussion and table are based on 7,356,289 shares of our
common stock outstanding as of September&nbsp;30, 2021, and exclude: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,698,249 shares of our common stock issuable upon the exercise of stock options outstanding as of
September&nbsp;30, 2021, at a weighted average exercise price of $11.71 per share; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,610,754 shares of our common stock reserved for issuance upon exercise of outstanding warrants having a
weighted average exercise price of $10.00 per share at September&nbsp;30, 2021;<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">283,755 shares of common stock reserved for issuance upon exercise of outstanding warrants having an exercise
price of $0.01 per share; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,170,721 shares of common stock reserved for issuance pursuant to the conversion of 11,707.21 shares of
preferred stock, based on the $10.00 conversion price in effect as of September&nbsp;30, 2021. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">488,031 shares of our common stock underlying the assumed conversion of convertible notes.<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that preferred stock has been converted or options or warrants
outstanding as of September&nbsp;30, 2021 have been or are exercised, investors purchasing shares in this offering could experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic
considerations, even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or equity-based securities, the issuance of these securities could
result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom236723_8"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our common stock and do not currently anticipate paying cash dividends in the foreseeable future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom236723_9"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We previously entered into a Controlled Equity Offering<SUP STYLE="font-size:85%; vertical-align:top">SM</SUP> Sales Agreement, or the sales agreement, with
Cantor Fitzgerald&nbsp;&amp;&nbsp;Co., or Cantor Fitzgerald, under which we may offer and sell shares of our common stock.&nbsp;Pursuant to this prospectus supplement, we may offer and sell shares of our common stock having an aggregate gross sales
price of up to $25.0&nbsp;million from time to time through Cantor Fitzgerald acting as sales agent. In our fiscal year ended December&nbsp;31, 2020, we sold a total of 77,644 shares of our common stock through Cantor Fitzgerald, our sales agent
under the sales agreement, for total gross proceeds of approximately $910,000, pursuant to a prospectus supplement dated August&nbsp;18, 2020 and an accompanying prospectus dated December&nbsp;21, 2018 included in a shelf registration statement on
Form <FONT STYLE="white-space:nowrap">S-3</FONT> filed with the Securities and Exchange Commission and declared effective on December&nbsp;21, 2018. A copy of the sales agreement was previously filed as an exhibit to our Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> filed with the Securities and Exchange Commission on August&nbsp;18, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon delivery of a placement notice and
subject to the terms and conditions of the sales agreement, Cantor Fitzgerald may offer and sell shares of our common stock by any method permitted by law deemed to be an &#147;at the market offering&#148; as defined in Rule&nbsp;415(a)(4)
promulgated under the Securities Act. We may instruct Cantor Fitzgerald not to sell common stock if the sales cannot be effected at or above the price designated by us from time to time. We or Cantor Fitzgerald may suspend the offering of common
stock upon notice and subject to other conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will pay Cantor Fitzgerald commissions, in cash, for its services in acting as agent in the sale of
our common stock. Cantor Fitzgerald is entitled to compensation at a commission rate of 3.0% of the gross sales price per share sold under the sales agreement. Because there is no minimum offering amount required as a condition to close this
offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. We have also agreed to reimburse Cantor Fitzgerald for certain specified expenses, including the reasonable and documented
fees and disbursements of its legal counsel in an amount not to exceed $50,000 for fees and disbursements in connection with the preparation and filing of this prospectus supplement. We estimate that the total expenses for the offering under this
prospectus supplement, excluding compensation and reimbursements payable to Cantor Fitzgerald under the terms of the Sales Agreement, will be approximately $65,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Settlement for sales of shares of common stock will occur on the second business day following the date on which any sales are made, or on some other date
that is agreed upon by us and Cantor Fitzgerald in connection with a particular transaction, in return for payment of the net proceeds to us. Sales of our common stock as contemplated in this prospectus supplement will be settled through the
facilities of The Depository Trust Company or by such other means as we and Cantor Fitzgerald may agree upon. There is no arrangement for funds to be received in an escrow, trust or similar arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald will use its commercially reasonable efforts, consistent with its sales and trading practices, to solicit offers to purchase the shares of
common stock under the terms and subject to the conditions set forth in the sales agreement. In connection with the sale of the shares of common stock on our behalf, Cantor Fitzgerald will be deemed to be an &#147;underwriter&#148; within the
meaning of the Securities Act and the compensation of Cantor Fitzgerald will be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification and contribution to Cantor Fitzgerald (and its partners, members,
directors, officers, employees and agents) against certain civil liabilities, including liabilities under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offering of shares of
our common stock pursuant to the Sales Agreement will terminate upon the termination of the sales agreement as permitted therein. We and Cantor Fitzgerald may each terminate the sales agreement at any time upon ten days&#146; prior notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald and its affiliates may in the future provide various investment banking, commercial banking and other financial services for us, our
subsidiaries and our affiliates, for which services they may in the future </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
receive customary fees. To the extent required by Regulation&nbsp;M, Cantor Fitzgerald will not engage in any market making activities involving our common stock while the offering is ongoing
under this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus in electronic format may be made available on a website
maintained by Cantor Fitzgerald and Cantor Fitzgerald may distribute this prospectus supplement and the accompanying prospectus electronically. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom236723_10"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the issuance of the Common Stock offered by this prospectus supplement will be passed upon for us by McCarter&nbsp;&amp; English, LLP, Newark,
New Jersey. Cantor Fitzgerald&nbsp;
&amp; Co. is being represented in connection with this offering by Cooley LLP, New York, New York. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom236723_11"></A>EXPERTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements as of December&nbsp;31, 2020 and 2019 and for the years then ended incorporated by reference in this prospectus supplement,
have been so incorporated in reliance on the report of Marcum LLP, an independent registered public accounting firm (the report on the financial statements contains an explanatory paragraph regarding our ability to continue as a going concern),
incorporated herein by reference, given on the authority of said firm as experts in auditing and accounting. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom236723_12">
</A>WHERE YOU CAN FIND MORE INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> under
the Securities Act with respect to the shares of common stock we are offering under this prospectus supplement utilizing a shelf registration process, which registration statement was declared effective on July&nbsp;2, 2021. This prospectus
supplement and the accompanying prospectus do not contain all of the information set forth in the registration statement and the amendments and exhibits to the registration statement. For further information with respect to us and the securities we
are offering under this prospectus supplement, we refer you to the registration statement and the amendments and thereto, and the exhibits and schedules filed as a part of the registration statement. We file annual, quarterly and current reports,
proxy statements and other information with the SEC. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, including us. The
SEC&#146;s Internet site can be found at <U>www.sec.gov</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom236723_13"></A>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; the information from other documents that we file with it, which means that we can disclose
important information to you by referring you to those documents. The information incorporated by reference is considered part of this prospectus supplement and the accompanying prospectus. Later information filed with the SEC will update and
supersede this information. The SEC&#146;s Internet site can be found at <U>www.sec.gov</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We incorporate by reference the documents listed below and
any future filings made with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus supplement until the termination of the offering of the shares covered by this prospectus supplement (other than
Current Reports furnished under Item 2.02 or Item 7.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> and exhibits filed on such form that are related to such items): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/872912/000156459021016962/dcth-10k_20201231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2020, filed with the SEC on March&nbsp;31, 2021; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the periods ended March&nbsp;31,
2021, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/872912/000156459021026362/dcth-10q_20210331.htm">May&nbsp;11, 2021</A>, June&nbsp;
30, 2021, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/872912/000156459021043029/dcth-10q_20210630.htm">August&nbsp;10, 2021</A> and September&nbsp;
30, 2021, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/872912/000156459021055636/dcth-10q_20210930.htm">November&nbsp;9, 2021</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/872912/000156459021009590/dcth-8k_20210223.htm">March&nbsp;1,
 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/872912/000119312521104082/d22722d8k.htm">April&nbsp;
1, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/872912/000119312521154966/d47677d8k.htm">May&nbsp;
7, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/872912/000156459021034909/dcth-8k_20210628.htm">June&nbsp;
29, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/872912/000119312521243492/d179551d8k.htm">August&nbsp;
11, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/872912/000119312521301066/d149734d8k.htm">October&nbsp;
18, 2021</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/872912/000119312521307965/d197160d8k.htm">October&nbsp;26, 2021</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock, which is registered under Section&nbsp;12 of the Exchange Act, in our
registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/872912/000119312520128421/d915262d8a12b.htm">Form <FONT STYLE="white-space:nowrap">8-A</FONT></A>, filed with the SEC on April&nbsp;30, 2020, including any amendments or
reports filed for the purpose of updating such description. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may request a copy of these filings, at no cost, by writing or
telephoning us at the following address or telephone number: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Delcath Systems, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1633 Broadway, Suite 22C </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">New York,
New York 10019 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attn: Corporate Secretary </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap">E-Mail:&nbsp;investorrelations@delcath.com</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone: <FONT STYLE="white-space:nowrap">(212)&nbsp;489-2100</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with Rule 412 of the Securities Act, any statement contained in a document incorporated by reference herein shall be deemed modified or
superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>$100,000,000 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g236723g70x52.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Preferred Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Senior
Debt Securities </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Units </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may from time to time issue, in one or more
series or classes, up to $100&nbsp;million in aggregate principal amount of our common stock, preferred stock, debt securities, warrants and/or units in one or more offerings. We may offer these securities separately or together in units, and we may
offer securities as may be issuable upon conversion, redemption, repurchase, exchange or exercise of any of the securities registered hereunder, including any applicable anti-dilution provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus provides a general description of the securities we may offer. Each time we offer securities, we will specify in the accompanying prospectus
supplement the terms of the securities being offered. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any free writing prospectus may also add,
update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as any documents incorporated by reference, before you invest
in our securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may sell these securities to or through underwriters and also to other purchasers or through agents. We will set forth the names of
any underwriters or agents, and any fees, conversions or discount arrangements, in an accompanying prospectus supplement. We may not sell any securities under this prospectus without delivery of the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is traded on The NASDAQ Capital Market under the symbol &#147;DCTH.&#148; On June&nbsp;24, 2021, the closing price for our common stock, as
reported on The NASDAQ Capital Market, was $11.04 per share. Our principal executive offices are located at 1633 Broadway, Suite 22C, New York, New York 10019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties referenced under the heading
&#147;</B><B><I><A HREF="#tx236723_3">Risk Factors</A></I></B><B>&#148; contained in this prospectus beginning on page 5 and any applicable prospectus supplement, and under similar headings in the other documents that are incorporated by reference
into this prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these
securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The
date of this prospectus is July 2, 2021. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx236723_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx236723_2">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx236723_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx236723_4">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx236723_5">DESCRIPTION OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx236723_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx236723_7">RATIO OF EARNINGS TO FIXED CHARGES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx236723_8">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx236723_9">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx236723_10">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx236723_11">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx236723_12">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx236723_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or SEC, utilizing a shelf registration process.
Under the shelf registration process, we may offer shares of our common stock and preferred stock, various series of debt securities, warrants and units to purchase any of such securities with a total value of up to $100,000,000 from time to time
under this prospectus at prices and on terms to be determined by market conditions at the time of offering. This prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities, we
will provide a prospectus supplement (which term includes, as applicable, the sales agreement prospectus filed with the registration statement of which this prospectus forms a part) that will describe the specific amounts, prices and other important
terms of the securities, including, to the extent applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">designation or classification; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">aggregate principal amount or aggregate offering price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maturity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">original issue discount, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">rates and times of payment of interest, dividends or other payments, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">redemption, conversion, exchange, settlement or sinking fund terms, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conversion, exchange or settlement prices or rates, if any, and, if applicable, any provisions for changes to or
adjustments in the conversion, exchange or settlement prices or rates and in the securities or other property receivable upon conversion, exchange or settlement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ranking; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictive covenants, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting or other rights, if any; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">important federal income tax considerations. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A prospectus supplement may include a discussion of risks or other special considerations applicable to us or the offered securities. A prospectus supplement
may also add, update or change information in this prospectus. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement, you must rely on the information in the prospectus supplement. Please
carefully read both this prospectus and the applicable prospectus supplement in their entirety together with additional information described under the heading &#147;Where You Can Find More Information&#148; in this prospectus. This prospectus may
not be used to offer or sell any securities unless accompanied by a prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The registration statement containing this prospectus,
including exhibits to the registration statement, provides additional information about us and the securities offered under this prospectus. The registration statement can be read on the SEC&#146;s website. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not authorized any broker-dealer, salesperson or other person to give any information or to make any representation other than those contained or
incorporated by reference in this prospectus and the accompanying prospectus supplement. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus or the accompanying prospectus
supplement. This prospectus and the accompanying prospectus supplement do not constitute an offer to sell or the solicitation of an offer to buy securities, nor do this prospectus and the accompanying prospectus supplement constitute an offer to
sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation. The information contained in this prospectus and the accompanying prospectus supplement speaks only
as of the date set forth on the cover page and may not reflect subsequent changes in our business, financial condition, results of operations and prospects even though this prospectus and any accompanying prospectus supplement is delivered or
securities are sold on a later date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx236723_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>In this prospectus, unless otherwise noted, the terms &#147;Delcath&#148;, &#147;Company&#148;, &#147;we&#148;, &#147;us&#148;, and &#147;our&#148; refer
to the ongoing business operations of Delcath Systems, Inc. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our lead product candidate, the HEPZATO<SUP
STYLE="font-size:85%; vertical-align:top">&#153;</SUP> KIT (melphalan hydrochloride for injection/hepatic delivery system), or HEPZATO<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP>, is a drug/device combination product. HEPZATO is
designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. HEPZATO has not been approved for sale in the United States. In Europe, our commercial product is a stand-alone medical
device having the same device components as the HEPZATO KIT but without the melphalan hydrochloride. The device is approved for sale under the trade name CHEMOSAT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Hepatic Delivery System for
Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, HEPZATO is
regulated as a combination drug and device by the United States Food and Drug Administration (FDA). Primary jurisdiction for regulation of HEPZATO has been assigned to the FDA&#146;s Center for Drug Evaluation and Research. The FDA has granted the
active moiety melphalan hydrochloride five orphan drug designations for the treatment of patients with ocular (uveal) melanoma, cutaneous melanoma, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and neuroendocrine tumors. The FDA has
granted the active moiety doxorubicin one orphan drug designation for the treatment of patients with hepatocellular carcinoma. In Europe, CHEMOSAT is regulated as a Class&nbsp;IIb medical device and received its CE Mark in 2012. We are
commercializing CHEMOSAT in select markets in the United Kingdom and the European Union, or the EU, where we believe the prospect of securing reimbursement coverage for the use of CHEMOSAT is strongest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our most advanced development program is the treatment of ocular melanoma liver metastases, or mOM, a type of primary liver cancer, with HEPZATO. HEPZATO is
being studied in the FOCUS Clinical Trial for Patients with Hepatic Dominant Ocular Melanoma (FOCUS Trial), a global registration clinical trial that is investigating objective response rate in mOM. The FOCUS Trial is being conducted at
approximately 30 sites in the United States and Europe. The FOCUS Trial initiated treatment on the final enrolled patient on October&nbsp;2, 2020. The primary endpoint of the FOCUS Trial is Objective Response Rate (ORR) as measured by RECISTv1.1, in
the Intent to Treat (ITT) population. The single arm trial was powered to demonstrate a superior ORR versus checkpoint inhibitors, one of the few mOM treatment categories with a significant amount of peer reviewed publications. The checkpoint
inhibitor ORR was calculated based on a meta-analysis covering 16 different publications which included 476 patients. The pooled overall response rate was 5.5% [95% CI: 3.6, 8.3]. To achieve statistical significance at a 95% Confidence Interval the
lower bound of the ORR for HEPZATO is required to exceed the 8.3% upper bound of the meta-analysis. Secondary endpoints include Duration of Response (DOR), Disease Control Rate (DCR), Overall Survival (OS), and Progression-Free Survival (PFS).
Additional exploratory outcome measures include time to objective response, hepatic progression-free survival, hepatic objective response, and quality of life, safety, and other pharmacokinetic measures. Initially, the trial was a randomized
controlled trial which was amended to a single arm trial given slow enrollment due to the rarity of ocular melanoma, absence of crossover to the experimental trial arm, competing clinical trials and the commercial availability of CHEMOSAT in Europe.
Included in the prespecified analyses are comparisons against the Best Alternative Care (BAC) arm which enrolled 32 patients prior to the amendment to a <FONT STYLE="white-space:nowrap">single-arm</FONT> trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have paused a global Phase 3 clinical trial of HEPZATO in patients with intrahepatic cholangiocarcinoma, (the ALIGN Trial) due to difficulties in
enrollment. In addition to the FOCUS Trial and the ALIGN Trial, our commercial development plan also includes a registry for CHEMOSAT cases performed in Europe and support of select investigator-initiated trials, or IITs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are currently reviewing the incidence, unmet need, available efficacy data and development requirements
for a broad set of liver cancers in order to select a portfolio of indications which will maximize the value of the HEPZATO platform. This may result in a restart of the ALIGN Trial. We believe that the disease states we are investigating and intend
to investigate are unmet medical needs that represent significant market opportunities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>FOCUS Trial Preliminary Analysis </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;31, 2021
Delcath released a preliminary analysis of the FOCUS trial data based on 87% of enrolled patients using prespecified analyses. An Independent Review Committee assessed an ORR of 29.2% [95% CI: 20.1, 39.8] in the ITT population, the lower bound of
which exceeded the upper bound of the predefined success criteria (8.3%) for the primary ORR endpoint. In the per protocol populations, evaluable patients in the HEPZATO arm had a statistically significant improvement over BAC in prespecified
endpoints including: ORR of 32.9% [95% CI: 22.8, 44.4] versus 13.8% [CI: 3.9, 31.7] for the BAC arm <FONT STYLE="white-space:nowrap">(Chi-square</FONT> P&lt;0.05), Median PFS of 9.0 months [95% CI: 6.2, 11.8] versus 3.1 months ([95% CI: 2.7, 5.7]
for the BAC arm (HR=0.41 p&lt;0.001), and DCR of 70.9% [95% CI: 59.6, 80.6] versus 37.9% [95% CI: 20.7, 57.7] for the BAC arm (p&lt;0.002). In this preliminary analysis, DOR and OS were not yet evaluable. Since not all patients were evaluable for
all time points, these preliminary analyses may change as data matures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the HEPZATO safety population of 94 patients, 38 patients (40.4%) experienced
a treatment-emergent serious adverse event. The most commonly reported treatment-emergent serious adverse events were thrombocytopenia (14.9% of patients), neutropenia (10.6% of patients), and leukopenia (4.2% of patients), which were
well-manageable. 5% of patients experienced treatment-emergent serious cardiac adverse events. In all cases the events resolved with no ongoing complications. There were no treatment-related deaths in the trial. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">COVID-19</FONT> </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to
the global outbreak of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> a novel strain of coronavirus that causes Coronavirus disease <FONT STYLE="white-space:nowrap">(COVID-19),</FONT> the Company
experienced an impact on certain areas of its business.&nbsp;These effects included a slowing of patient recruitment in the FOCUS Trial and a reduction in the pace at which we can monitor data at our clinical trial sites.&nbsp;The resulting delay in
completing enrollment and additional time required to monitor data caused our announcement for the <FONT STYLE="white-space:nowrap">top-line</FONT> data from our FOCUS Trial to shift to early 2021 and to be modified to a preliminary
analysis.&nbsp;We intend to submit a New Drug Application (NDA) to the FDA in the first quarter of 2022 for the treatment of mOM once the FOCUS Trial has been completed.&nbsp;The ability to achieve this goal is contingent on our ability to monitor
data at our clinical sites and therefore the timeline may shift as access to the clinical sites changes in response to the rapidly evolving <FONT STYLE="white-space:nowrap">situation.&nbsp;COVID-19</FONT> has caused us to experience an increase in
volatility in EU commercial product revenue.&nbsp;The results of the FOCUS Trial should also support securing reimbursement coverage for the use of CHEMOSAT in Europe. Additional impacts of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on our
business may arise that we are not aware of currently. The ultimate impact of the pandemic on the Company&#146;s results of operations, financial position, liquidity, or capital resources cannot be reasonably estimated at this time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Medical Device Directive Transition to Medical Device Regulation </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The European Commission recently reviewed the Medical Device Directive legislative framework and promulgated REGULATION (EU) 2017/745 OF THE EUROPEAN
PARLIAMENT AND OF THE COUNCIL of 5&nbsp;April 2017 on medical devices, amending Directive 2001/83/EC, Regulation EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC. This new Medical Device
Regulation became effective on May&nbsp;25, 2017, marking the start of a <FONT STYLE="white-space:nowrap">3-year</FONT> transition period for manufacturers selling medical devices in Europe to comply with the new medical device regulation, or MDR,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which governs all facets of medical devices. The transition task is highly complex and touches every aspect of product development, manufacturing production, distribution, and post marketing
evaluation.&nbsp;As a result of the worldwide <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, on April&nbsp;17, 2020, the European Parliament adopted the European Commission&#146;s proposal to postpone the implementation of the MDR (EU)
2017/745 by 12 months. This urgently drafted proposal to delay the MDR is in response to the exceptional circumstances associated with the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and the potential impact it may have had on the MDR
implementation. Delcath can continue to operate under our current MDD CE Mark until April 2024, while the Notified Bodies work through related backlog. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effectively addressing these changes will require a complete review of our device operations to determine what is necessary to comply. We do not believe the
MDR regulatory changes will impact our business at this time, though implementation of the medical device legislation may adversely affect our business, financial condition and results of operations or restrict our operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated in the State
of Delaware in August 1988. Our principal executive offices are located at 1633 Broadway, Suite 22C, New York, New York 10019. Our telephone number is (212) <FONT STYLE="white-space:nowrap">489-2100.</FONT> Our website address is
<U>http://www.delcath.com</U>. Information contained in our website does not constitute any part of, and is not incorporated into, this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx236723_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before making an investment decision, you should carefully consider the risks described under &#147;Risk Factors&#148; in the applicable prospectus
supplement, together with all of the other information appearing in this prospectus or incorporated by reference into this prospectus and any applicable prospectus supplement, in light of your particular investment objectives and financial
circumstances. Our business, financial condition or results of operations could be materially adversely affected by any of these risks. The trading price of our securities could decline due to any of these risks, and you may lose all or part of your
investment. This prospectus and the incorporated documents also contain forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a
result of certain factors, including the risks mentioned elsewhere in this prospectus. You should also consider the risks, uncertainties and assumptions discussed under the heading &#147;Risk Factors&#148; included in our most recent Annual Report
on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> which is on file with the SEC and is incorporated herein by reference, and which may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx236723_4"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can
be identified by words such as &#147;intends,&#148; &#147;believes,&#148; &#147;anticipates,&#148; &#147;indicates,&#148; &#147;plans,&#148; &#147;expects,&#148; &#147;suggests,&#148; &#147;may,&#148; &#147;would,&#148; &#147;should,&#148;
&#147;potential,&#148; &#147;designed to,&#148; &#147;will,&#148; &#147;ongoing,&#148; &#147;estimate,&#148; &#147;forecast,&#148; &#147;predict,&#148; &#147;could,&#148; and similar references, although not all forward-looking statements contain
these words. Forward-looking statements are neither historical facts nor assurances of future performance. These statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and
strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are
difficult to predict and many of which are outside of our control. Risks that could cause actual results to vary from expected results expressed in our forward-looking statements include, but are not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding sufficiency of our cash resources, anticipated capital requirements and our need for
additional financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commencement of future clinical trials and the results and timing of those clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully commercialize CHEMOSAT and HEPZATO, generate revenue and successfully obtain
reimbursement for the procedure and Delcath Hepatic Delivery system; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress and results of our research and development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations about the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and any disruption or impact
to our operations due to the pandemic; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission and timing of applications for regulatory approval and approval thereof; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully source certain components of CHEMOSTAT and HEPZATO and enter into supplier contracts;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully manufacture CHEMOSAT and HEPZATO; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully negotiate and enter into agreements with distribution, strategic and corporate
partners; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates of potential market opportunities and our ability to successfully realize these opportunities.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our actual results and financial condition may differ materially from those indicated in the forward-looking statements as a result of
the foregoing factors, as well as those identified in this prospectus or applicable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prospectus supplement under the heading &#147;Risk Factors&#148; and in other filings the Company periodically makes with the SEC. Therefore, you should not rely unduly on any of these
forward-looking statements. Forward-looking statements contained in this prospectus speak as of the date hereof and the Company does not undertake to update any of these forward-looking statements to reflect a change in its views or events or
circumstances that occur after the date of this report. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx236723_5"></A>DESCRIPTION OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may offer shares of our common stock and preferred stock, various series of debt securities, warrants, and units to purchase any such securities with a
total value of up to $100,000,000 from time to time under this prospectus at prices and on terms to be determined by market conditions at the time of the offering. Each time we offer a type or series of securities, we will provide a prospectus
supplement that will describe the specific amounts, prices and other important terms of the securities. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Authorized Capital Stock
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a description of the material terms of our capital stock included in our Amended and Restated Certificate of Incorporation, as
amended (our &#147;Certificate of Incorporation&#148;), and our Amended and Restated <FONT STYLE="white-space:nowrap">By-Laws</FONT> (our <FONT STYLE="white-space:nowrap">&#147;By-Laws&#148;).</FONT> This description of our capital stock does not
purport to be complete and is subject to, and qualified in its entirety by, our Certificate of Incorporation and <FONT STYLE="white-space:nowrap">By-Laws,</FONT> which are exhibits to the registration statement of which this prospectus forms a part,
and by applicable law. The terms of our common stock and preferred stock may also be affected by Delaware law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">40,000,000 shares of common stock, par value $0.01 per share; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">10,000,000 shares of undesignated preferred stock, par value $0.01 per share. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is the only class or series of our securities which has been registered under Section&nbsp;12 of the Securities Exchange Act of 1934, as
amended, and is listed on The Nasdaq Capital Market under the symbol &#147;DCTH&#148;. Of the 10,000,000 authorized shares of preferred stock, an aggregate of 52,960 shares are designated as Series E Preferred Stock or Series <FONT
STYLE="white-space:nowrap">E-1</FONT> Preferred Stock. As of June&nbsp;25, 2021, there were outstanding 7,021,839 shares of our common stock and an aggregate of 14,986.59 shares of Series E Preferred Stock and Series
<FONT STYLE="white-space:nowrap">E-1</FONT> Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;25, 2021, there were 2,475,000 shares of the Company&#146;s common stock
reserved under the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, of which 1,881,608 shares remained available to be issued. As of June&nbsp;25, 2021, we had (a) 3,773,266 shares of common stock issuable upon the exercise of outstanding
warrants, including (i) 11 common stock warrants, (ii) 1,765,355 Series E and Series <FONT STYLE="white-space:nowrap">E-1</FONT> Warrants, (iii) 1,851,900 Series F Warrants, and (iv) 156,000 Series F
<FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants at a weighted average exercise price of $9.59 per share and (b) 1,091,891 shares of common stock issuable upon the exercise of outstanding options with a weighted average exercise price of
$12.69 per share. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Voting rights.</I></B> Our shares of common stock are entitled to voting rights for the election of directors and for all other matters
requiring stockholder action. Each holder of common stock is entitled to one vote for each share, except as otherwise required by law, and subject to the rights of the holders of preferred stock. The common stock does not have cumulative voting
rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dividend rights.</I></B> Holders of our common stock are entitled to receive such
dividends, if any, as may be declared from time to time by our board of directors in its discretion out of funds legally available therefor. Holders of common stock share ratably in any dividends declared by our board of directors, subject to any
preferential dividend rights of any outstanding preferred stock. Dividends consisting of shares of common stock may be paid to holders of shares of common stock. We do not intend to pay cash dividends in the foreseeable future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation rights.</I></B> Upon our liquidation or dissolution, the holders of our common stock will be entitled to receive, pro rata,
all assets remaining available for distribution to stockholders after payment of all liabilities and provision for the liquidation of any shares of preferred stock at the time outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other Rights and Restrictions</I></B>. Our common stock has no preemptive or other subscription rights, and there are no conversion
rights or redemption or sinking fund provisions with respect to such stock. Our common stock is not subject to redemption by us. Our Certificate of Incorporation and Bylaws do not restrict the ability of a holder of common stock to transfer the
stockholder&#146;s shares of common stock. If we issue shares of common stock under this prospectus, the shares will be fully <FONT STYLE="white-space:nowrap">paid&nbsp;and&nbsp;non-assessable&nbsp;and&nbsp;will</FONT> not have, or be subject to,
any preemptive or similar rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Market Information. </I></B>Our common stock is traded on the Nasdaq Capital Markets under the
symbol &#147;DCTH&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Transfer Agent and Registrar</I></B>. The transfer agent and registrar for our common stock is American
Stock Transfer&nbsp;&amp; Trust Company, LLC. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Preferred Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has the authority to issue up to 10,000,000 shares of preferred stock in one or more series and to determine the rights and preferences
of the shares of any such series without stockholder approval, of which 14,986.59 shares of Series E Preferred Stock and Series <FONT STYLE="white-space:nowrap">E-1</FONT> Preferred Stock, or, collectively, the Preferred Stock, is outstanding as of
June&nbsp;25, 2021. Our board of directors may issue preferred stock in one or more series and has the authority to fix the designation and powers, rights and preferences and the qualifications, limitations, or restrictions with respect to each
class or series of such class without further vote or action by the stockholders. The ability of our board of directors to issue preferred stock without stockholder approval could have the effect of delaying, deferring or preventing a change of
control of us or the removal of existing management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with a private placement in July 2019, the Company filed a certificate of designation
of Preferences, Rights and Limitations of Series E Preferred Stock with the Secretary of State of the State of Delaware, or the Delaware SOS, for the purpose of amending its Certificate of Incorporation to classify and designate 40,000 authorized
but unissued shares of the Company&#146;s preferred stock as shares of Series E Preferred Stock. The preferences, conversion and other rights, voting powers, restrictions, limitations as to dividends and other distributions, qualifications and terms
and conditions of redemption of the Series E Preferred Stock are set forth in the Certificate of Designation and are described below. The certificate of designation became effective on July&nbsp;11, 2019 upon acceptance for filing by the Delaware
SOS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with a private placement in August 2019, the Company filed a certificate of designation of Preferences, Rights and Limitations of
Series <FONT STYLE="white-space:nowrap">E-1</FONT> Preferred Stock with Delaware SOS, for the purpose of amending its Certificate of Incorporation to classify and designate 12,960 authorized but unissued shares of the Company&#146;s preferred stock
as shares of Series <FONT STYLE="white-space:nowrap">E-1</FONT> Preferred Stock. The preferences, conversion and other rights, voting powers, restrictions, limitations as to dividends and other distributions, qualifications and terms and conditions
of redemption of the Series <FONT STYLE="white-space:nowrap">E-1</FONT> Preferred Stock are set forth in the certificate of designation and are described below. The certificate of designation became effective on August&nbsp;15, 2019 upon acceptance
for filing by the Delaware SOS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Conversion rights.</I></B><B> </B>Each share of the Series E Preferred Stock and
Series <FONT STYLE="white-space:nowrap">E-1</FONT> Preferred Stock has a par value of $0.01 per share and a stated value equal to $1,000, or the Stated Value, and is convertible at any time at the option of the holder into the number of shares of
common stock determined by dividing the stated value by the conversion price of $10.00, subject to certain limitations and adjustments, or the Conversion Price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Voting rights. </I></B>The Preferred Stock will vote on an as converted basis on all matters submitted to the holders of common stock
for approval, subject to certain limitations and exceptions. The affirmative vote of the holders of a majority of the then outstanding shares of Preferred Stock is required to increase the number of authorized shares of Preferred Stock or to alter
or change adversely the powers, preferences or rights given to the Preferred Stock, or to amend the Company&#146;s organizational documents in any manner that adversely affects the rights of the holders of the Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dividend rights.</I></B><B> </B>Except for certain adjustments, the holders of Preferred Stock will be entitled to receive dividends on
shares of Preferred Stock equal (on an as if converted basis) to and in the same form as dividends paid on shares of the common stock. Any such dividends that are not paid to the holders of Preferred Stock will increase the Stated Value. No other
dividends will be paid on shares of Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation rights. </I></B>Upon any liquidation of the Company, the holders
of Preferred Stock will be entitled to receive out of the assets of the Company an amount equal to the Stated Value plus any accrued and unpaid dividends thereon for each share of Preferred Stock before any distribution or payment will be made to
the holders of the common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Convertible Notes</B>. Immediately following the closing of the Company&#146;s July 2019 private placement, the
Company&#146;s 8% Senior Secured Promissory Notes (the &#147;Convertible Notes&#148;) were amended, pursuant to a note amending agreement dated as of July&nbsp;15, 2019 between the Company and the holders, to provide that the outstanding principal
amount of the Convertible Notes and any accrued and unpaid interest thereon are convertible, at the option of the holder, into shares of Series E Preferred Stock at the price of $1,500. Holders of the Convertible Notes, upon conversion of the
Convertible Notes to Series E Preferred Stock, and subsequent conversion of such shares of Series E Preferred Stock into common stock, may offer such shares of common stock for resale pursuant to a supplemental prospectus to be filed in connection
with this Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Restricted Share</B>s. Officers and directors who hold shares of restricted common stock may offer such shares for
resale pursuant to a supplemental prospectus to be filed in connection with this Registration Statement . </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Delaware Law and
Our Certificate of Incorporation and Bylaws </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain provisions of our Certificate of Incorporation and Bylaws could have the effect of making it more
difficult for our stockholders to replace management at a time when a substantial number of stockholders might favor a change in management. These provisions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">providing for a staggered board; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorizing the board of directors to fill vacant directorships or increase the size of its board of directors.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, our board of directors has the authority to issue up to 10,000,000 shares of preferred stock in one or more series and to
determine the rights and preferences of the shares of any such series without stockholder approval. Any series of preferred stock is likely to be senior to the common stock with respect to dividends, liquidation rights and, possibly, voting rights.
The board&#146;s ability to issue preferred stock may have the effect of discouraging unsolicited acquisition proposals, thus adversely affecting the market price of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to Section&nbsp;203 of the Delaware General Corporation Law, which prohibits Delaware corporations from engaging in a wide range of specified
transactions with any interested stockholder, defined to include, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
among others, any person other than such corporation and any of its majority owned subsidiaries who own 15% or more of any class or series of stock entitled to vote generally in the election of
directors, unless, among other exceptions, the transaction is approved by (i)&nbsp;our board of directors prior to the date the interested stockholder obtained such status or (ii)&nbsp;the holders of
<FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares of each class or series of stock entitled to vote generally in the election of directors, not including those shares owned by the interested stockholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Staggered Board of Directors. </I></B>Our Certificate of Incorporation and Bylaws provide that our board of directors be classified into
three classes of directors of approximately equal size. As a result, in most circumstances, a person can gain control of our board only by successfully engaging in a proxy contest at two or more annual meetings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Authorized but Unissued Shares. </I></B>Our authorized but unissued shares of preferred stock are available for future issuances without
stockholder approval and could be utilized for a variety of corporate purposes, including future offerings to raise additional capital, corporate acquisitions, employee benefit plans and stockholder rights plans. The existence of authorized but
unissued and unreserved preferred stock could render more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Senior Debt Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description,
together with the additional information we may include in any applicable prospectus supplement and in any related free writing prospectuses, summarizes the material terms and provisions of the senior debt securities that we may offer under this
prospectus. While the terms summarized below will apply generally to any senior debt securities that we may offer, we will describe the particular terms of any senior debt securities in more detail in the applicable prospectus supplement. The terms
of any senior debt securities offered under a prospectus supplement may differ from the terms described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue senior debt securities from
time to time in one or more distinct series. The debt securities will be senior debt securities (also referred to as &#147;debt securities&#148;). Senior debt securities will be issued under a senior indenture, which form of indenture is filed
herewith as Exhibit 4.1. If we issue senior debt securities pursuant to an indenture, in the applicable prospectus supplement we will specify the trustee under such indenture. We will include in a supplement to this prospectus the specific terms of
debt securities being offered, including the terms, if any, on which debt securities may be convertible into or exchangeable for common stock, preferred stock or other debt securities. The statements and descriptions in this prospectus or in any
prospectus supplement regarding provisions of debt securities and any indentures are summaries of these provisions, do not purport to be complete and are subject to, and are qualified in their entirety by reference to, all of the provisions of the
debt securities and the indentures (including any amendments or supplements we may enter into from time to time which are permitted under the debt securities or an indenture). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise specified in a prospectus supplement, the debt securities will be direct unsecured obligations of the Company. Any debt securities designated
as senior will rank equally with any of our other senior and unsubordinated debt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement will set forth the terms of the
senior debt securities or any series thereof, including, if applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the senior debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limit upon the aggregate principal amount of the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be issued as registered securities, bearer securities or both, and any
restrictions on the exchange of one form of debt securities for another and on the offer, sale and delivery of the debt securities in either form; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates on which the principal amount of the debt securities will mature; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the debt securities bear interest, the rate or rates at which the debt securities bear interest, or the method
for determining the interest rate, and the date or dates from which interest will accrue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the debt securities bear interest, the dates on which interest will be payable, or the method for determining
such dates, and the regular record dates for interest payments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the place or places where the payment of principal, any premium and interest will be made, where the debt
securities may be surrendered for transfer or exchange and where notices or demands to or upon us may be served; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any optional redemption provisions, which would allow us to redeem the debt securities in whole or in part;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sinking fund or other provisions that would obligate us to redeem, repay or purchase the debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the currency in which the debt securities will be issuable is United States dollars, the denominations in
which any registered securities will be issuable, if other than denominations of $1,000 and any integral multiple thereof, and the denominations in which any bearer securities will be issuable, if other than the denomination of $5,000;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if other than the entire principal amount, the portion of the principal amount of debt securities which will be
payable upon a declaration of acceleration of the maturity of the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the events of default and covenants relevant to the debt securities, including, the inapplicability of any event
of default or covenant set forth in the indenture relating to the debt securities, or the applicability of any other events of defaults or covenants in addition to the events of default or covenants set forth in the indenture relating to the debt
securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name and location of the corporate trust office of the applicable trustee under the indenture for such series
of debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if other than United States dollars, the currency in which the debt securities will be paid or denominated;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the debt securities are to be payable, at our election or the election of a holder of the debt securities, in
a currency other than that in which the debt securities are denominated or stated to be payable, the terms and conditions upon which that election may be made, and the time and manner of determining the exchange rate between the currency in which
the debt securities are denominated or stated to be payable and the currency in which the debt securities are to be so payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation of the original currency determination agent, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the debt securities are issuable as indexed securities, the manner in which the amount of payments of
principal, any premium and interest will be determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the debt securities do not bear interest, the dates on which we will furnish to the applicable trustee the
names and addresses of the holders of the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if other than as set forth in an indenture, provisions for the satisfaction and discharge or defeasance or
covenant defeasance of that indenture with respect to the debt securities issued under that indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date as of which any bearer securities and any global security will be dated if other than the date of
original issuance of the first debt security of a particular series to be issued; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and under what circumstances we will pay additional amounts to
<FONT STYLE="white-space:nowrap">non-United</FONT> States holders in respect of any tax assessment or government charge; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be issued in whole or in part in the form of a global security or securities
and, in that case, any depositary and global exchange agent for the global security or securities, whether the global form shall be permanent or temporary and, if applicable, the exchange date; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if debt securities are to be issuable initially in the form of a temporary global security, the circumstances
under which the temporary global security can be exchanged for definitive debt securities and whether the definitive debt securities will be registered securities, bearer securities or will be in global form and provisions relating to the payment of
interest in respect of any portion of a global security payable in respect of an interest payment date prior to the exchange date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent and manner to which payment on or in respect of debt securities will be subordinated to the prior
payment of our other liabilities and obligations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether payment of any amount due under the debt securities will be guaranteed by one or more guarantors,
including one or more of our subsidiaries; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be convertible and the terms of any conversion provisions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the forms of the debt securities; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the debt securities, which terms shall not be inconsistent with the requirements of the Trust
Indenture Act of 1939, as amended. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that does not limit the aggregate principal
amount of debt securities that we may issue up to $100,000,000 and provides that we may issue debt securities from time to time in one or more series under the form of indenture attached to this prospectus, in each case with the same or various
maturities, at par or at a discount. Unless indicated in a prospectus supplement, we may issue additional debt securities of a particular series without the consent of the holders of the debt securities of such series outstanding at the time of the
issuance. Any such additional debt securities, together with all other outstanding debt securities of that series, will constitute a single series of debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to disclose any restrictive covenants for any issuance or series of debt securities in the applicable prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DESCRIPTION OF WARRANTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue
warrants for the purchase of shares of our common stock or preferred stock or of senior debt securities.&nbsp;We may issue warrants independently or together with other securities, and the warrants may be attached to or separate from any offered
securities.&nbsp;Each series of warrants will be issued under a separate warrant agreement to be entered into between us and the investors or a warrant agent.&nbsp;The following summary of material provisions of the warrants and warrant agreements
are subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable to a particular series of warrants.&nbsp;The terms of any warrants offered under a prospectus supplement
may differ from the terms described below.&nbsp;We urge you to read the applicable prospectus supplement and any related free writing prospectus, as well as the complete warrant agreements and warrant certificates that contain the terms of the
warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The particular terms of any issue of warrants will be described in the prospectus supplement relating to the issue.&nbsp;Those terms may
include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares of common stock or preferred stock purchasable upon the exercise of warrants to purchase
such shares and the price at which such number of shares may be purchased upon such exercise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation, stated value and terms (including, without limitation, liquidation, dividend, conversion and
voting rights) of the series of preferred stock purchasable upon exercise of warrants to purchase preferred stock; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the principal amount of debt securities that may be purchased upon exercise of a debt warrant and the exercise
price for the warrants, which may be payable in cash, securities or other property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date, if any, on and after which the warrants and the related debt securities, preferred stock or common
stock will be separately transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any rights to redeem or call the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the right to exercise the warrants will commence and the date on which the right will expire;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">United States Federal income tax consequences applicable to the warrants; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any additional terms of the warrants, including terms, procedures, and limitations relating to the exchange,
exercise and settlement of the warrants. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of equity warrants will not be entitled: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to vote, consent or receive dividends; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receive notice as stockholders with respect to any meeting of stockholders for the election of our directors or
any other matter; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exercise any rights as stockholders of Delcath. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each warrant will entitle its holder to purchase the principal amount of debt securities or the number of shares of preferred stock or common stock at the
exercise price set forth in, or calculable as set forth in, the applicable prospectus supplement.&nbsp;Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the
specified time on the expiration date that we set forth in the applicable prospectus supplement.&nbsp;After the close of business on the expiration date, unexercised warrants will become void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A holder of warrant certificates may exchange them for new warrant certificates of different denominations, present them for registration of transfer and
exercise them at the corporate trust office of the warrant agent or any other office indicated in the applicable prospectus supplement.&nbsp;Until any warrants to purchase debt securities are exercised, the holder of the warrants will not have any
rights of holders of the debt securities that can be purchased upon exercise, including any rights to receive payments of principal, premium or interest on the underlying debt securities or to enforce covenants in the applicable
indenture.&nbsp;Until any warrants to purchase common stock or preferred stock are exercised, the holders of the warrants will not have any rights of holders of the underlying common stock or preferred stock, including any rights to receive
dividends or payments upon any liquidation, dissolution or winding up on the common stock or preferred stock, if any. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DESCRIPTION OF
UNITS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue units consisting of any combination of the other types of securities offered under this prospectus in one or more series.&nbsp;We
may evidence each series of units by unit certificates that we will issue under a separate agreement.&nbsp;We may enter into unit agreements with a unit agent.&nbsp;Each unit agent will be a bank or trust company that we select.&nbsp;We will
indicate the name and address of the unit agent in the applicable prospectus supplement relating to a particular series of units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following
description, together with the additional information included in any applicable prospectus supplement, summarizes the general features of the units that we may offer under this prospectus.&nbsp;You should read any prospectus supplement and any free
writing prospectus that we may authorize to be provided to you related to the series of units being offered, as well as the complete unit agreements that contain the terms of the units.&nbsp;Specific unit agreements will contain additional important
terms and provisions and we will file as an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from another report that we file with the SEC, the form of each unit agreement relating
to units offered under this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we offer any units, certain terms of that series of units will be described in the applicable prospectus
supplement, including, without limitation, the following, as applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the series of units; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identification and description of the separate constituent securities comprising the units;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices at which the units will be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date, if any, on and after which the constituent securities comprising the units will be separately
transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of certain United States federal income tax considerations applicable to the units; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the units and their constituent securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx236723_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will retain broad discretion over the use of the net proceeds from the sale of our securities offered hereby. Except as described in any prospectus
supplement, we currently anticipate using the net proceeds from the sale of our securities offered hereby primarily for general corporate purposes, which include, but are not limited to, funding our commercialization and manufacturing development,
other research and development activities and for general and administrative expenses. We may also use a portion of the net proceeds to pay off outstanding indebtedness, if any, and/or acquire or invest in complementary businesses, products and
technologies. Further, from time to time we may evaluate acquisition opportunities and engage in related discussions with other companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pending the
use of the net proceeds, we intend to invest the net proceeds in short-term, interest-bearing, investment-grade securities. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx236723_7">
</A>RATIO OF EARNINGS TO FIXED CHARGES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we offer debt securities and/or preferred equity securities under this prospectus, then we will, if
required at that time, provide a ratio of earnings to fixed charges and/or ratio of combined fixed charges and preference dividends to earnings, respectively, in the applicable prospectus supplement for such offering. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx236723_8"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and/or selling stockholders may sell the securities covered by this prospectus from time to time in one or more offerings. Registration of the securities
covered by this prospectus does not mean, however, that those securities will necessarily be offered or sold. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may sell the securities separately or
together: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through one or more underwriters or dealers in a public offering and sale by them; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">directly to investors; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through agents. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may sell the securities from time to time: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in one or more transactions at a fixed price or prices, which may be changed from time to time;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the times of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will describe the method of distribution of the securities and the terms of the offering in the prospectus supplement. Any discounts or concessions allowed
or <FONT STYLE="white-space:nowrap">re-allowed</FONT> or paid to dealers may be changed from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If underwriters are used in the sale of any
securities, the securities will be acquired by the underwriters for their own account and may be resold from time to time in one or more transactions described above. The securities may be either offered to the public through underwriting syndicates
represented by managing underwriters, or directly by underwriters. Generally, the underwriters&#146; obligations to purchase the securities will be subject to conditions precedent and the underwriters will be obligated to purchase all of the
securities if they purchase any of the securities. We may use underwriters with whom we have a material relationship. We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may authorize underwriters, dealers or agents to solicit offers by certain purchasers to purchase the securities from us at the public offering price set
forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. The contracts will be subject only to those conditions set forth in the prospectus supplement, and the
prospectus supplement will set forth any commissions we pay for solicitation of these contracts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may enter into derivative transactions with third
parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement indicates, in connection with those derivatives, the third parties may sell securities covered
by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party may use securities pledged by us or borrowed from us or others to settle those sales or to close out any related open
borrowings of stock, and may use securities received from us in settlement of those derivatives to close out any related open borrowings of stock. The third party in such sale transactions will be an underwriter and will be identified in the
applicable prospectus supplement or in a post-effective amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Underwriters, dealers and agents may be entitled to indemnification by us against
certain civil liabilities, including liabilities under the Securities Act, or to contribution with respect to payments made by the underwriters, dealers or agents, under agreements between us and the underwriters, dealers and agents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may grant underwriters who participate in the distribution of securities an option to purchase additional securities to cover over-allotments, if any, in
connection with the distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Underwriters, dealers or agents may receive compensation in the form of discounts, concessions or commissions from us
or our purchasers, as their agents in connection with the sale of securities. These underwriters, dealers or agents may be considered to be underwriters under the Securities Act. As a result, discounts, commissions or profits on resale received by
the underwriters, dealers or agents may be treated as underwriting discounts and commissions. The prospectus supplement will identify any such underwriter, dealer or agent and describe any compensation received by them from us. Any initial public
offering price and any discounts or concessions allowed or <FONT STYLE="white-space:nowrap">re-allowed</FONT> or paid to dealers may be changed from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise specified in the related prospectus supplement, all securities we offer, other than common stock, will be new issues of securities with no
established trading market. Any underwriters may make a market </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. Any common stock sold pursuant to a prospectus supplement will be listed
for trading on the NASDAQ Capital Market or other principal market for our common stock. We may apply to list any series of debt securities, preferred stock, warrants or units on an exchange, but we are not obligated to do so. Therefore, there may
not be liquidity or a trading market for any series of securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any underwriter may engage in over-allotment transactions, stabilizing transactions,
short-covering transactions and penalty bids in accordance with Regulation M under the Exchange Act. Over-allotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the
underlying security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids
permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a covering transaction to cover short positions. Those activities may cause the price of the securities to be
higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. We make no representation or prediction as to the direction or magnitude of any effect that such transactions may have on the price
of the securities. For a description of these activities, see the information under the heading &#147;Underwriting&#148; or &#147;Plan of Distribution&#148; in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Underwriters, broker-dealers or agents who may become involved in the sale of the common stock may engage in transactions with and perform other services for
us in the ordinary course of their business for which they receive compensation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx236723_9"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The legality of the issuance of the securities being offered hereby and the binding nature of any debt securities, warrants or units being offered hereby is
being passed upon by McCarter&nbsp;&amp; English, LLP, Newark, New Jersey. The legality of the securities for any underwriters, dealers or agents will be passed upon by counsel as may be specified in the applicable prospectus supplement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx236723_10"></A>EXPERTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
consolidated financial statements as of December&nbsp;31, 2020 and 2019 and for each of the two years in the period ended December&nbsp;31, 2020 incorporated by reference in this prospectus have been so incorporated in reliance on the report of
Marcum, LLP, an independent registered public accounting firm, incorporated herein by reference, given on the authority of said firm as experts in auditing and accounting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx236723_11"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference into this prospectus the information contained in other documents we file with the SEC, which means that we can
disclose important information to you by referring you to those documents. Any statement contained in any document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded, for purposes of this
prospectus, to the extent that a statement contained in or omitted from this prospectus, or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein, modifies or supersedes such statement. Any such
statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus. We incorporate by reference the documents listed below which have been filed by us: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/872912/000156459021016962/dcth-10k_20201231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2020, filed with the SEC on March&nbsp;31, 2021, including those portions of the Form <FONT STYLE="white-space:nowrap">10-K</FONT> incorporated by reference from
our definitive proxy statement filed on <A HREF="http://www.sec.gov/Archives/edgar/data/872912/000119312521108254/d153004ddef14a.htm">April&nbsp;7, 2021</A>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/872912/000156459021026362/dcth-10q_20210331.htm">Form
 <FONT STYLE="white-space:nowrap">10-Q</FONT></A> for the period ended March&nbsp;31, 2021, filed with the SEC on May&nbsp;11, 2021; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/872912/000156459021009590/dcth-8k_20210223.htm">March&nbsp;1,
 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/872912/000119312521104082/d22722d8k.htm">April&nbsp;
1, 2021</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/872912/000119312521154966/d47677d8k.htm">May&nbsp;7, 2021</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The description of our common stock contained in our registration on <A HREF="http://www.sec.gov/Archives/edgar/data/872912/000119312520128421/d915262d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-Al2B</FONT></A> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-16133)</FONT> filed with the SEC on April&nbsp;30, 2020, including any amendment or report filed for the purpose of updating such description.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All documents we file with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, except as to any portion of any
report or documents that is not deemed filed under such provisions, (1)&nbsp;on or after the date of filing of the registration statement containing this prospectus and prior to the effectiveness of the registration statement and (2)&nbsp;on or
after the date of this prospectus until the earlier of the date on which all of the securities registered hereunder have been sold or the registration statement of which this prospectus is a part has been withdrawn, shall be deemed incorporated by
reference in this prospectus and to be a part of this prospectus from the date of filing of those documents and will be automatically updated and, to the extent described above, supersede information contained or incorporated by reference in this
prospectus and previously filed documents that are incorporated by reference in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nothing in this prospectus shall be deemed to
incorporate information furnished but not filed with the SEC pursuant to Item 2.02, 7.01 or 9.01 of Form <FONT STYLE="white-space:nowrap">8-K.</FONT> Upon written or oral request, we will provide without charge to each person, including any
beneficial owner, to whom a copy of the prospectus is delivered a copy of any or all of the reports or documents incorporated by reference herein (other than exhibits to such documents, unless such exhibits are specifically incorporated by reference
herein). You may request a copy of these filings, at no cost, by writing or telephoning us at the following address: Delcath Systems, Inc., 1633 Broadway, Suite 22C, New York, New York 10019. We maintain a website at <U>www.delcath.com</U>. You may
access our definitive proxy statements on Schedule 14A, annual reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> and periodic amendments to those reports filed or furnished pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act with the SEC free of charge at our website as soon as reasonably practicable after such
material is electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not incorporated by reference in, and is not part of, this prospectus. We have not authorized any one to
provide you with any information that differs from that contained in this prospectus. Accordingly, you should not rely on any information that is not contained in this prospectus. You should not assume that the information in this prospectus is
accurate as of any date other than the date of the front cover of this prospectus. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx236723_12"></A>WHERE YOU CAN FIND MORE
INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are required to file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains an
Internet site that contains all reports and other information that we file electronically with the SEC. The address of that website is www.sec.gov. Copies of certain information filed by us with the SEC are also available on our website at
www.delcath.com. Our website is not a part of this prospectus and is not incorporated by reference in this prospectus, and you should not consider the contents of our website in making an investment decision with respect to our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have filed a registration statement, of which this prospectus is a part, covering the securities offered hereby. As allowed by SEC rules, this prospectus
does not include all of the information contained in the Registration Statement and the included exhibits, financial statements and schedules. You are referred to the Registration Statement, the included exhibits, financial statements and schedules
for further information. Statements contained in this prospectus as to the contents of any contract or other document are not necessarily complete, and in each instance we refer you to the copy of the contract or document filed as an exhibit to the
registration statement, each such statement being qualified in all respects by such reference. This prospectus is qualified in its entirety by such other information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g236723g70x52.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Up to $25,000,000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
SUPPLEMENT </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g236723g97w67.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:72pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>November&nbsp;9, 2021 </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g236723g70x52.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g236723g70x52.jpg
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M4U5Q@9&3E-'3)$)BP1<S5'*"H<(6-**QU-4E)D1TI*7#_]H # ,!  (1 Q$
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M.+"/_P!.JB7@/Q?O?Q8.(XV4^;#$OM64S\.^$^YM$;1ETJS_ -7982?+G/\
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MMF_:C/E.39(AKL1WXR2/SDQ^-%%(F06!%[^)]XEV'P]6%9N%RQ'!3KM[X0(
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MUQ9N%EKM^[<=BSVK=BPS$Y),TSR$Y_XM=3TX%JU*M91Q6O7AA51[A%&J ?\
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M,=^D9L7[W3_YA*_S?6V^HZ/PW/[$?]+3#TB;ZU;[1^_H^D9L7[W3_P"82O\
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M42EE!DD=4#,JYRP!4LR4*<8DLB")6=8TS&&:21LE8XXU5GDD(!(2-68A6.,
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M8OW:?RT?,?IO\+-?_I*#_9='K;=/SC>_BI_OZ.A!^1B_=I_+1\Q^F_PLU_\
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M5^/4_I5:=;9ZU^6;;4MW[ER)&W."]9CBKTDJY$$-6I9@:662PQF>RI:.-(1
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MFWC4B\:&XX2G)&]:FLE@@Q7Z'BUBP$.76,,0]UF)46>4&;)U\&O2$?+E8UO
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M)&F-4/VYRZ1^QW+2]KJH.V->PXF,7"Q5]7.+AU2:KI&0[CD3'VA169P*,6L
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)1HZ-&CHT:__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g236723g97w67.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g236723g97w67.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2-V4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M      IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O
M;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I
M;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M     %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB
M;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!O
MX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M      !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M          !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O
M; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L
M=                %1O<"!5;G1&(U)L=                %-C;"!5;G1&
M(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P
M4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M#6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M        /X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))
M30/S       )           ! #A"24TG$       "@ !          (X0DE-
M _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $
M,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M '   /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z   .$))300(       0     0   D
M  )      #A"24T$'@      !      X0DE-!!H      S4    &
M      "!   "L          !                          $
M     K    "!                      $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   "!     %)G:'1L;VYG   "L     9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG    @0    !2
M9VAT;&]N9P   K     #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M   X0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$
M%       !     4X0DE-! P     &.4    !    H    !X   '@   X0
M&,D &  !_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="
M(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M     0  ]M8  0    #3+4A0("
M                             !%C<')T   !4    #-D97-C   !A
M &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "
M+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D
M   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T
M96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/
M" QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@
M0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M     !)S4D="($E%0S8Q.38V+3(N,0
M                                    6%E:(        /-1  $    !
M%LQ865H@                     %A96B        !OH@  ./4   .06%E:
M(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P
M.B\O=W=W+FEE8RYC:
M                  !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U
M;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                    9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@
M0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC
M92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                     '9I97<      !.D_@ 47RX $,\4  /MS  $$PL
M UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                 H\    "<VEG(     !#4E0@8W5R=@        0
M!0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R
M '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0#; .
MY0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%% 4P!4@%9 6 !9P%N
M 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!\@'Z @,"# (4 AT"
M)@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+! LL"U0+@ NL"]0,
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M0\!$ T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M             /_A/7)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_
M>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK
M8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z
M>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C Q
M,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z
M<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M
M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q
M+C,O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY!8W)O8F%T($1I<W1I;&QE
M<B Q,"XQ+C$V("A7:6YD;W=S*3PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O(CX*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y04V-R
M:7!T-2YD;&P@5F5R<VEO;B U+C(N,CPO>&UP.D-R96%T;W)4;V]L/@H@(" @
M(" @(" \>&UP.DUO9&EF>41A=&4^,C R,"TP-RTR,U0P,3HU,3HP."LP-3HS
M,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR
M,#(P+3 W+3(S5# Q.C,S.C$T*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @
M(" @(" @/'AM<#I-971A9&%T841A=&4^,C R,"TP-RTR,U0P,3HU,3HP."LP
M-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @
M(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O
M,2XQ+R(^"B @(" @(" @(#QD8SIT:71L93X*(" @(" @(" @(" @/')D9CI!
M;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L
M="(^36EC<F]S;V9T(%=O<F0@+2 U-C$X-2!$96QC871H(%!R;W-P96-T=7,@
M4W5P<&QE;65N=#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @
M(" @(" @(#PO9&,Z=&ET;&4^"B @(" @(" @(#QD8SIC<F5A=&]R/@H@(" @
M(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3YR<C$W
M-C,V,CPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @
M(#PO9&,Z8W)E871O<CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F
M/"]D8SIF;W)M870^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN
M<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @
M(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z
M<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O
M=7)C95)E9B,B/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED
M.CDT-#0R.38S-3A#0T5!,3%",C$X.3(R1C(W0S-#.#<X/"]X;7!-33I);G-T
M86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.CDS
M-#0R.38S-3A#0T5!,3%",C$X.3(R1C(W0S-#.#<X/"]X;7!-33I$;V-U;65N
M=$E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD
M:60Z.3,T-#(Y-C,U.$-#14$Q,4(R,3@Y,C)&,C=#,T,X-S@\+WAM<$U-.D]R
M:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @
M(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.CDS-#0R.38S-3A#0T5!
M,3%",C$X.3(R1C(W0S-#.#<X/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(P+3 W+3(S5# Q.C4Q.C X*S U
M.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F
M='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%
M=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H
M86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV
M960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A
M<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E
M+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HY-#0T,CDV,S4X
M0T-%03$Q0C(Q.#DR,D8R-T,S0S@W.#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @
M(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,"TP-RTR,U0P,3HU,3HP
M."LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\
M+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP
M34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A
M;F-E240^>&UP+FEI9#HY,S0T,CDV,S4X0T-%03$Q0C(Q.#DR,D8R-T,S0S@W
M.#PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M
M96YT240^>&UP+F1I9#HY,S0T,CDV,S4X0T-%03$Q0C(Q.#DR,D8R-T,S0S@W
M.#PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I
M;F%L1&]C=6UE;G1)1#YX;7 N9&ED.CDS-#0R.38S-3A#0T5!,3%",C$X.3(R
M1C(W0S-#.#<X/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @
M(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @
M(" @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO
M=&]S:&]P+S$N,"\B/@H@(" @(" @(" \<&AO=&]S:&]P.D-O;&]R36]D93XT
M/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO
M;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$(
M "D W ,!$0 "$0$#$0'_Q  ?   " @$% 0$            )"@@+ 0 " P8'
M!03_Q !&$  !! (! @0#! 4'"0D    " 0,$!08'" D1 !(3(10Q00H6(G$5
M48&QP1<8&3)AD:$C)28V2&5R@O W.$)SIK2VP];_Q  < 0 " @,! 0
M       '"  & 00% @/_Q !-$0 " 0,# P(#!0,'!P@+   ! @,$!1$&$B$
M!S$3010B43)"87&Q%2.!%R0S4I&AP18T-4-R@O E)F)SLM'2TT5355:#A9.4
ML\+A_]H # ,!  (1 Q$ /P!^RPL(-5!EV=G,C5]= CO2YTZ:^U%APXL=LG7Y
M,J2^;;+$=EH"<=>=,6VP%2,D%%7QZC1Y72.-&DD=E1(T4L[LQPJJJ@LS,>
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M;0),-T6!<<BO,D:^;V1T;+H;0-?:Z*NHK!024]5#%40O-#ZLFR1 P#M*7DR
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M][)\%[3W^CU_(?J.A9?/\^G_ #;J>?#'_4AS_P B)_\ ;XIFJO\ /%_VI?\
MM#JUZ7_S1O\ 9C__ &ZFCXJO5G'C^+?J>L+\Q_/^"^,>X_(_JO6>M%\E_)?W
M>,]3K2?+]I?O7Q.IUA/ZQ?\ +^[Q.IUM+^LG_%_ ?&/<_D/U;J=<GC/4Z__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
